0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          In patients with heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril–valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this effect is superior to that induced by other renin–angiotensin system (RAS) inhibitors is not well known.

          Methods

          HFrEF patients treated with S/V ( n = 795) were compared, by propensity score matching, with a historical cohort of 831 HFrEF patients (non-S/V group) treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (RAS inhibitors). All patients were also treated with beta-blockers and shared the same protocol with repeat echocardiogram 8–12 months after starting therapy. The difference-in-difference (DiD) analysis was used to evaluate the impact of S/V on CR indices between the two groups.

          Results

          After propensity score matching, compared to non-S/V group ( n = 354), S/V group ( n = 354) showed a relative greater reduction in end-diastolic and end-systolic volume index (ESVI), and greater increase in ejection fraction (DiD estimator =  + 5.42 mL/m 2, P = 0.0005; + 4.68 mL/m 2, P = 0.0009, and + 1.76%, P = 0.002, respectively). Reverse LVR (reduction in ESVI ≥ 15% from baseline) was more prevalent in S/V than in non-S/V group (34% vs 26%, P = 0.017), while adverse LVR (aLVR, increase in ESVI at follow-up ≥ 15%) was more frequent in non-S/V than in S/V (16% vs 7%, P < 0.001). The beneficial effect of S/V on CR over other RAS inhibitors was appreciable across a wide range of patient’s age and baseline end-diastolic volume index, but it tended to attenuate in more dilated left ventricles ( P for interaction = NS for both).

          Conclusion

          In HFrEF patients treated with beta-blockers, sacubitril/valsartan is associated with a relative greater benefit in LV reverse remodeling indices than other RAS inhibitors.

          Graphical abstract

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00392-023-02306-0.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: not found
          • Article: not found

          2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

            The propensity score is the probability of treatment assignment conditional on observed baseline characteristics. The propensity score allows one to design and analyze an observational (nonrandomized) study so that it mimics some of the particular characteristics of a randomized controlled trial. In particular, the propensity score is a balancing score: conditional on the propensity score, the distribution of observed baseline covariates will be similar between treated and untreated subjects. I describe 4 different propensity score methods: matching on the propensity score, stratification on the propensity score, inverse probability of treatment weighting using the propensity score, and covariate adjustment using the propensity score. I describe balance diagnostics for examining whether the propensity score model has been adequately specified. Furthermore, I discuss differences between regression-based methods and propensity score-based methods for the analysis of observational data. I describe different causal average treatment effects and their relationship with propensity score analyses.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

              The rapid technological developments of the past decade and the changes in echocardiographic practice brought about by these developments have resulted in the need for updated recommendations to the previously published guidelines for cardiac chamber quantification, which was the goal of the joint writing group assembled by the American Society of Echocardiography and the European Association of Cardiovascular Imaging. This document provides updated normal values for all four cardiac chambers, including three-dimensional echocardiography and myocardial deformation, when possible, on the basis of considerably larger numbers of normal subjects, compiled from multiple databases. In addition, this document attempts to eliminate several minor discrepancies that existed between previously published guidelines. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
                Bookmark

                Author and article information

                Contributors
                erberto.carluccio@unipg.it
                Journal
                Clin Res Cardiol
                Clin Res Cardiol
                Clinical Research in Cardiology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                1861-0684
                1861-0692
                21 September 2023
                21 September 2023
                2024
                : 113
                : 6
                : 856-865
                Affiliations
                [1 ]Cardiology and Cardiovascular Pathophysiology, S. Maria Della Misericordia Hospital, University of Perugia, ( https://ror.org/00x27da85) Perugia, Italy
                [2 ]Thoracic and Vascular Department, University of Pisa, ( https://ror.org/03ad39j10) Pisa, Italy
                [3 ]Department of Cardiology, University Hospital Foggia, Foggia, Italy
                [4 ]Department of Biomedical, Dental Sciences, and Morphofunctional Imaging, University of Messina, ( https://ror.org/05ctdxz19) Messina, Italy
                [5 ]Chair of Cardiology, Department of Medicine, Surgery and Dentistry, University of Salerno, ( https://ror.org/0192m2k53) Fisciano, Italy
                [6 ]GRID grid.7637.5, ISNI 0000000417571846, Department of Cardiology, , University of Brescia and ASST Spedali Civili Di Brescia, ; Brescia, Italy
                [7 ]Cardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, Le Scotte Hospital, University of Siena, ( https://ror.org/01tevnk56) Siena, Italy
                [8 ]GRID grid.416052.4, ISNI 0000 0004 1755 4122, Heart Failure Unit, , AORN Dei Colli, Monaldi Hospital, ; Naples, Italy
                [9 ]GRID grid.419425.f, ISNI 0000 0004 1760 3027, Division of Cardiology, , Fondazione I.R.C.C.S. Policlinico San Matteo, ; Pavia, Italy
                [10 ]GRID grid.4691.a, ISNI 0000 0001 0790 385X, Department of Translational Medical Sciences, , Federico II University, ; Naples, Italy
                [11 ]CERICLET-Centro Ricerca Clinica E Traslazionale, University of Perugia, ( https://ror.org/00x27da85) Perugia, Italy
                Author information
                http://orcid.org/0000-0002-9296-4397
                Article
                2306
                10.1007/s00392-023-02306-0
                11108945
                37733084
                94c55927-ccdd-4f61-ab60-7cdfe92dbf65
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 10 June 2023
                : 5 September 2023
                Funding
                Funded by: Università degli Studi di Perugia
                Categories
                Original Paper
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2024

                Cardiovascular Medicine
                sacubitril/valsartan,neprilysin inhibitors,arni,cardiac remodeling,heart failure, ras inhibitors

                Comments

                Comment on this article